title: Pharmacological characterization of cultivated neuronal networks: relevance to synaptogenesis and synaptic connectivity.
abstract: Mental disorders, such as schizophrenia or Alzheimer's disease, are associated with impaired synaptogenesis and/or synaptic communication. During development, neurons assemble into neuronal networks, the primary supracellular mediators of information processing. In addition to the orchestrated activation of genetic programs, spontaneous electrical activity and associated calcium signaling have been shown to be critically involved in the maturation of such neuronal networks. We established an in vitro model that recapitulates the maturation of neuronal networks, including spontaneous electrical activity. Upon plating, mouse primary hippocampal neurons grow neurites and interconnect via synapses to form a dish-wide neuronal network. Via live cell calcium imaging, we identified a limited period of time in which the spontaneous activity synchronizes across neurons, indicative of the formation of a functional network. After establishment of network activity, the neurons grow dendritic spines, the density of which was used as a morphological readout for neuronal maturity and connectivity. Hence, quantification of neurite outgrowth, synapse density, spontaneous neuronal activity, and dendritic spine density allowed to study neuronal network maturation from the day of plating until the presence of mature neuronal networks. Via acute pharmacological intervention, we show that synchronized network activity is mediated by the NMDA-R. The balance between kynurenic and quinolinic acid, both neuro-active intermediates in the tryptophan/kynurenine pathway, was shown to be decisive for the maintenance of network activity. Chronic modulation of the neurotrophic support influenced the network formation and revealed the extreme sensitivity of calcium imaging to detect subtle alterations in neuronal physiology. Given the reproducible cultivation in a 96-well setup in combination with fully automated analysis of the calcium recordings, this approach can be used to build a high-content screening assay usable for neurotoxicity screening, target identification/validation, or phenotypic drug screening.
authors.affiliation: Laboratory of Cell Biology & Histology, University of Antwerp, Groenenborgerlaan 171, 2020, Antwerp, Belgium.
authors.forename: Peter
authors.initials: P
authors.lastname: Verstraelen
authors.forename: Isabel
authors.initials: I
authors.lastname: Pintelon
authors.forename: Rony
authors.initials: R
authors.lastname: Nuydens
authors.forename: Frans
authors.initials: F
authors.lastname: Cornelissen
authors.forename: Theo
authors.initials: T
authors.lastname: Meert
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Timmermans
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D051379:Mice; D009415:Nerve Net / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D055495:Neurogenesis / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology; D013569:Synapses / Q000187:drug effects / Q000502:physiology*
chemical_list: D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate
references.citation: Nat Neurosci. 2001 Nov;4 Suppl:1207-14
references.pmid: 11687831
references.citation: Behav Brain Res. 2011 Aug 10;221(2):505-14
references.pmid: 21130117
references.citation: J Neurosci. 1995 Oct;15(10):6509-20
references.pmid: 7472413
references.citation: Brain Res. 1985 Mar 25;330(2):265-72
references.pmid: 2985194
references.citation: Neuroscientist. 2012 Aug;18(4):326-41
references.pmid: 21670426
references.citation: Synapse. 2011 Jan;65(1):41-53
references.pmid: 20506382
references.citation: Science. 1996 Nov 15;274(5290):1133-8
references.pmid: 8895456
references.citation: Neuroscience. 2002;115(4):1089-108
references.pmid: 12453482
references.citation: J Biomol Screen. 2013 Aug;18(7):807-19
references.pmid: 23606652
references.citation: J Neurosci. 2011 Sep 28;31(39):14032-6
references.pmid: 21957264
references.citation: J Neural Eng. 2011 Oct;8(5):056008
references.pmid: 21841241
references.citation: Curr Alzheimer Res. 2013 Mar;10(3):316-23
references.pmid: 23036017
references.citation: Nat Protoc. 2006;1(5):2406-15
references.pmid: 17406484
references.citation: Trends Neurosci. 2012 Apr;35(4):240-9
references.pmid: 22240240
references.citation: Eur J Neurosci. 2010 Jun;31(12):2178-84
references.pmid: 20550565
references.citation: Neurosci Lett. 2001 Nov 2;313(1-2):96-8
references.pmid: 11684348
references.citation: Eur J Pharmacol. 1981 Jul 10;72(4):411-2
references.pmid: 6268428
references.citation: J Alzheimers Dis. 2011;24 Suppl 2:199-209
references.pmid: 21441658
references.citation: Biol Psychiatry. 2001 Oct 1;50(7):521-30
references.pmid: 11600105
references.citation: Neurosci Biobehav Rev. 2011 Jan;35(3):848-70
references.pmid: 20951727
references.citation: Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13176-81
references.pmid: 17656555
references.citation: Neuropsychopharmacology. 2013 Apr;38(5):743-52
references.pmid: 23299933
references.citation: Trends Neurosci. 2012 Oct;35(10):607-18
references.pmid: 22717267
references.citation: J Neurosci. 1994 Nov;14(11 Pt 1):6695-706
references.pmid: 7965070
references.citation: Trends Neurosci. 2001 Jun;24(6):353-60
references.pmid: 11356508
references.citation: Annu Rev Physiol. 2009;71:261-82
references.pmid: 19575680
references.citation: Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5855-60
references.pmid: 21427228
references.citation: Nat Neurosci. 2011 Mar;14(3):285-93
references.pmid: 21346746
references.citation: J Neurosci. 2001 Oct 1;21(19):7463-73
references.pmid: 11567036
references.citation: J Neurosci Methods. 2008 Aug 15;173(1):27-33
references.pmid: 18585786
references.citation: Mol Psychiatry. 2014 Mar;19(3):334-41
references.pmid: 23459468
references.citation: Brain Res Bull. 2010 Sep 30;83(3-4):140-6
references.pmid: 20433911
references.citation: Neurochem Int. 1997 Feb;30(2):233-7
references.pmid: 9017671
references.citation: Prog Neurobiol. 2009 Oct;89(2):125-33
references.pmid: 19560509
references.citation: Cell. 2005 Feb 11;120(3):421-33
references.pmid: 15707899
references.citation: Brain Res. 2008 Oct 15;1235:21-30
references.pmid: 18602907
references.citation: Assay Drug Dev Technol. 2005 Dec;3(6):623-36
references.pmid: 16438658
references.citation: Biol Psychiatry. 2006 May 15;59(10):929-39
references.pmid: 16427028
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:35-48
references.pmid: 22349576
references.citation: J Neurophysiol. 2010 Aug;104(2):1052-60
references.pmid: 20554850
references.citation: PLoS One. 2009 Jul 22;4(7):e6344
references.pmid: 19623258
references.citation: J Pharmacol Sci. 2013;121(3):185-91
references.pmid: 23449491
references.citation: Cancer Res. 1957 Jan;17(1):15-20
references.pmid: 13413830
references.citation: Neurochem Int. 1999 May;34(5):359-72
references.pmid: 10397363
references.citation: Neuron. 1993 Feb;10(2):267-78
references.pmid: 8439412
references.citation: Trends Neurosci. 2006 Jul;29(7):414-418
references.pmid: 16713634
references.citation: Neuropharmacology. 2007 Mar;52(4):1151-9
references.pmid: 17320117
references.citation: Neuroscience. 2007 Feb 23;144(4):1229-40
references.pmid: 17184929
references.citation: Neuropharmacology. 2012 Mar;62(3):1230-41
references.pmid: 21195721
references.citation: Methods. 1999 Jun;18(2):215-21
references.pmid: 10356353
references.citation: Adv Med Sci. 2010;55(2):204-11
references.pmid: 20639188
references.citation: Cell Tissue Res. 2005 Mar;319(3):349-58
references.pmid: 15726425
references.citation: J Neurosci. 1995 Oct;15(10):6498-508
references.pmid: 7472412
references.citation: Trends Pharmacol Sci. 2013 Feb;34(2):136-43
references.pmid: 23123095
references.citation: Curr Opin Genet Dev. 2011 Jun;21(3):256-61
references.pmid: 21277192
references.citation: Eur J Neurosci. 2011 Jun;33(12):2187-202
references.pmid: 21615557
references.citation: Trends Neurosci. 2009 Aug;32(8):421-31
references.pmid: 19615761
references.citation: Neurobiology. 1972;2(3):97-105
references.pmid: 4572654
references.citation: Glia. 2003 Mar;41(4):371-81
references.pmid: 12555204
references.citation: Eur J Pharmacol. 1996 Jan 18;296(1):1-8
references.pmid: 8720470
references.citation: J Neurosci. 1988 Apr;8(4):1454-68
references.pmid: 3282038
references.citation: J Neurosci. 1995 Jan;15(1 Pt 1):1-11
references.pmid: 7823120
references.citation: Eur J Neurosci. 2011 Apr;33(8):1351-65
references.pmid: 21395862
references.citation: Mol Cell Neurosci. 2011 Jun;47(2):93-9
references.pmid: 21440632
references.citation: Neurobiol Dis. 2004 Dec;17(3):455-61
references.pmid: 15571981